New 2026 clinical guidance points to inconsistent cardiovascular follow-up for cancer survivors. Here's how health systems can close the gap with a risk-stratified, scalable surveillance pathway.
More than 18.6 million people in the United States are living after a cancer diagnosis, and that number is projected to reach 22.4 million by 2035 as earlier detection and better treatments extend survival across nearly every cancer type.[1] For a growing share of that population, the most significant long-term health threat isn't a cancer recurrence — it's cardiovascular disease. Anthracycline chemotherapy, HER2-targeted agents, chest and mediastinal radiation, certain tyrosine kinase inhibitors, and immune checkpoint inhibitors are all associated with elevated cardiovascular risk, and that risk can emerge years after treatment ends, well outside the window when oncology teams are typically watching closely.
Cardio-oncology has matured into a recognized subspecialty over the past decade, with dedicated guidelines, specialty clinics at academic centers, and a growing evidence base.[2] But most cancer survivors are not treated at academic cardio-oncology centers. They are followed, if they are followed at all, by primary care physicians and community oncologists that might not prioritize cardiovascular surveillance. Two clinical publications from earlier this year make clear how uneven that follow-up still is and why closing the gap doesn't require a new specialty clinic, just a better pathway.
Cardiovascular Disease Is a Leading Long-Term Threat, Not a Rare Complication
The link between certain cancer treatments and later cardiovascular disease is well established. Survivors of breast cancer, lymphoma, and childhood cancers who received cardiotoxic therapy face measurably elevated rates of heart failure, coronary artery disease, arrhythmia, and stroke compared with the general population. The 2022 ESC Guidelines on Cardio-Oncology, developed with the European Hematology Association, the European Society for Radiotherapy and Oncology, and the International Cardio-Oncology Society, were created specifically because cardiovascular disease had become common enough — and consequential enough — among cancer patients and survivors to warrant a dedicated clinical framework covering risk assessment before, during, and after treatment.[2]
That framework has continued to develop. The American College of Cardiology's cardio-oncology coverage this year has included guidance on cardiovascular toxicity in survivors of childhood cancer and the role of structured exercise in cardio-oncology care, reflecting a field that is actively refining how long-term risk should be monitored and managed rather than treating it as settled science.[3] For health systems building or maturing a survivorship program, that ongoing refinement is a signal worth acting on now, before cardiovascular follow-up becomes an expected — or audited — component of survivorship care.
New Research Points to a Persistent Gap in Post-Treatment Follow-Up
Two publications from 2026 illustrate why this matters operationally, not just clinically.
In May, the International Cardio-Oncology Society and the Multinational Association of Supportive Care in Cancer published a joint clinical practice statement on the prevention and management of cardiovascular disease in adults with cancer, aimed at giving clinicians outside specialty cardio-oncology centers a usable framework for risk assessment and follow-up.[4]
The following April, researchers published a cross-sectional analysis in the journal Cardio-Oncology examining how existing clinical practice guidelines address cardiovascular care in adult survivors after active treatment ends.[5] Taken together, the two publications point in the same direction: professional societies increasingly agree that structured cardiovascular surveillance belongs in survivorship care, but the guidance survivors actually receive still varies widely depending on where they are treated and which specialists are involved.
What Risk-Stratified Cardiovascular Surveillance Looks Like in Practice
The clearest lesson from current guidance is that not every survivor needs the same level of cardiovascular follow-up, and treating everyone the same is part of why gaps persist — high-risk patients get lost in a population where most people don't need intensive monitoring. A workable pathway starts with treatment history: patients who received anthracyclines above established cumulative dose thresholds, HER2-targeted therapy, chest or mediastinal radiation, or combination regimens carry meaningfully higher risk than survivors treated with regimens that carry minimal cardiac exposure. Layering in traditional cardiovascular risk factors — hypertension, diabetes, smoking history, age at treatment — refines that stratification further and identifies the subset of survivors who genuinely warrant echocardiography, biomarker monitoring, or a cardiology referral, rather than a blanket recommendation that overwhelms primary care capacity without meaningfully improving outcomes.
This is where the framework needs to be explicit rather than implicit. A survivorship care plan that lists "received doxorubicin" as a historical fact is not the same as a pathway that flags a specific patient as high-risk, specifies a follow-up interval, and routes that recommendation to whoever is actually managing the patient's care years later. The difference between documentation and a functioning pathway is what determines whether cardiovascular risk gets acted on or quietly falls through the handoff between oncology and primary care.
Building the Pathway Without a New Clinic or New Headcount
Health systems don't need to stand up a cardio-oncology subspecialty clinic to close this gap — most survivors don't need one, and building toward that as a first step would misallocate resources that are already stretched. What they need is a structured way to identify cardiovascular risk from existing treatment data, apply consistent risk-stratification criteria, and generate the right next step automatically: a primary care flag for moderate-risk survivors, a cardiology referral for high-risk survivors, and standard reassurance and lifestyle guidance for the rest.
This is precisely the kind of work that scales well when it's built into a survivorship care plan rather than handled through individual clinician memory or ad hoc chart review. Treatment history already captured for a survivorship care plan can drive automated risk stratification; risk-appropriate follow-up recommendations can populate the same care plan without requiring a nurse navigator to manually research guidelines for every patient; and escalation to cardiology can happen based on defined criteria rather than depending on whether a particular clinician happened to flag it. None of this requires additional full-time staff — it requires the underlying data structure and workflow logic to route existing information to the right decision point.
Why This Belongs in the Survivorship Care Plan, Not a Separate Referral
The temptation when a new risk category gains attention is to build a parallel process for it — a separate cardio-oncology intake, a separate tracking spreadsheet, a separate follow-up call. That approach adds exactly the kind of operational burden that makes survivorship programs hard to sustain, and it fragments a patient's care further at the moment they most need continuity. Cardiovascular risk assessment belongs inside the same survivorship care plan that already tracks a patient's treatment history, surveillance schedule, and psychosocial needs — stratified, documented, and routed like every other late-effects consideration, not carved out as a special case.
As the evidence base for cardio-oncology continues to mature and guidance from IC-OS, MASCC, and cardiology societies converges toward more consistent recommendations, health systems that have already built the infrastructure to act on treatment-history-driven risk will be positioned to adopt updated criteria quickly. Those still managing survivorship follow-up manually will find each guideline update harder to operationalize, not easier.
Sources
National Cancer Institute, Office of Cancer Survivorship. "Statistics and Graphs." Citing Wagle NS, Nogueira L, Devasia TP, et al. "Cancer treatment and survivorship statistics, 2025." CA: A Cancer Journal for Clinicians. 2025;75(4):308-340. https://cancercontrol.cancer.gov/ocs/statistics
European Society of Cardiology. "2022 ESC Guidelines on Cardio-Oncology." https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/cardio-oncology/
American College of Cardiology. Cardio-Oncology clinical topic coverage, including "Cardiovascular Toxicity in Patients Treated for Childhood Cancer" (May 2026) and coverage of exercise in cardio-oncology practice (January 2026). https://www.acc.org/Clinical-Topics/Cardio-Oncology
Dent S, et al. "Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement." Supportive Care in Cancer. 2026. https://pubmed.ncbi.nlm.nih.gov/42209784/
Ayoson J, et al. "Cardiovascular care in adult cancer survivorship post-therapy: a cross-sectional analysis of clinical practice guidelines." Cardio-Oncology. 2026. https://pubmed.ncbi.nlm.nih.gov/42057201/